Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1787306 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $27.99Day +0.47%Mkt cap $3.5B1Y +92.0%Off 52W high −11.9%Vol (1Y) 58.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,629 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest10.8% of sh out |
| Days to cover9.3d |
| 13F net flow (QoQ)+1.90% |
| Top-10 13F concentration52.8% |
| Next report (est.)2026-08-01 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$415.6M |
| Earnings (TTM)-$2.4M |
| ROE−9.3% |
| Net margin−4.3% |
| Debt / equity0.58× |
| Sales growth 3Y367.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−3.6% |
| 1Y+92.0% |
| 3Y+156.6% |
| 5Y+20.0% |
| Since incept. (ann.)+3.9% |
Total return through 2026-07-30 · series begins 2020-01-31. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)58.7% |
| Ann. volatility (3Y)75.3% |
| Sharpe (1Y)1.36 |
| Sharpe (3Y)0.79 |
| Max drawdown (1Y)−37.5% |
| Max drawdown (3Y)−83.1% |
| Beta (3Y vs SPY)2.25 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 12.3M | $290M | 9.94% | +3.0% |
| Frazier Life Sciences Management, L.P. | 9.9M | $233M | 7.96% | +0.0% |
| BlackRock, Inc. | 9.2M | $217M | 7.42% | +1.1% |
| Rubric Capital Management LP | 8.3M | $195M | 6.67% | +0.0% |
| STATE STREET CORP | 6.3M | $148M | 5.08% | +14.7% |
| Polar Capital Holdings Plc | 5.7M | $134M | 4.57% | +2.0% |
| JENNISON ASSOCIATES LLC | 5.0M | $117M | 4.02% | −26.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.9M | $115M | 3.93% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 106.9% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 16,879,909 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$0.09 | — | $105.4M | +60.1% |
| 2025-12-31 | 2026-02-25 | — | — | $129.5M | +81.5% |
| 2025-09-30 | 2025-10-28 | $0.06 | — | $99.2M | +121.7% |
| 2025-06-30 | 2025-08-06 | −$0.13 | — | $81.5M | +164.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-01 is ESTIMATED from filing cadence (median gap 87d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
